Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Blog Article

Editorial summary Inhibitors of Skin Care Formula poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a Supercharger Pulleys clinical hurdle.Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.